Phase 2 N=10 Transplanting Hepatitis C Lungs Into Negative Lung Recipients
Lung Diseases
Primary: Subject Sustained Virologic Response (SVR-12) at 12-weeks Post-treatment — 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=25 Human Fetal Liver Cell Transplantation in Chronic Liver Failure
Liver Cirrhosis
Primary: Patient Survival — 5; 6; 4; 10 participants — p=0.4340
N/A N=300 OCS Liver PROTECT Trial: Preserving and Assessing Donor Livers for Transplantation
Liver Transplantation · Liver Preservation for Transplant
Primary: Participants With Early Liver Allograft Dysfunction (EAD) — 27; 44; 27; 47 Participants — p=<0.0001
Phase 2 N=93 Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)
Reperfusion Injury
Primary: Peak Aspartate Aminotransferase Within First 72h Post Transplant — 1262.9; 1451.2 U/L
Phase 4 N=100 Intraoperative Glucose Control in Liver Transplant
Liver Transplant
Primary: Infection Rates — 27; 26; 11; 7 Participants — p=0.841
Phase 3 N=70 De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
Liver Carcinoma
Primary: Percentage of Participants Surviving at One and Four Years After Liver Transplant — 85; 77 percentage of participants
N/A N=115 Study to Compare the Incidence of Biliary Complications After Liver Transplantation
Liver Transplant; Complications
Primary: Number of Participants With Biliary Complications — 19; 12 participants
N/A N=15 Intravenous Interferon During Liver Transplant
Hepatitis C · Cirrhosis
Primary: HCV RNA Result — 924,082; 3,731,749 IU/ml
Phase 2 N=110 A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation
Liver Failure
Primary: The Incidence of Acute Kidney Injury (AKI) as Assessed by Change in Serum Creatinine From Baseline to 30 Days Post-transplant — .01; .06 mg/dL
N/A N=49 Hypothermic Machine Preservation-Phase 2
Liver Damage
Primary: Patient Survival at One Year Post-Transplantation — 19; 19 participants
Phase 4 N=164 Study of Glycemic Control on Liver Transplantation Outcomes
Evidence of Liver Transplantation · Hyperglycemia · Rejection
Primary: Rejection of Liver Transplant — 17; 20 participants — p=0.709
Phase 4 N=25 HCV Positive Heart Donors
Heart Failure
Primary: Sustained Virologic Response After Treatment — 24 Participants
Phase 1 N=18 Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation
Liver Cirrhosis · Hepatocellular Carcinoma · Evidence of Liver Transplantation
Primary: Side Effect of Cadaveric Donor Liver NK Cell Infusion — 0; 0 participants
Phase 2 N=5 The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
Liver Transplant · Hepatitis C
Primary: Adverse Events Due to Sofosbuvir/Velpatasvir (Epclusa) — 0; 0 Participants
Phase 4 N=10 Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
End Stage Renal Disease · Hepatitis C
Primary: Viral Response at Week 12 — 10 Participants
Phase 3 N=102 Surgical Site Infections After Liver Transplantation Based on Perioperative Antibiotics
Liver Transplantation · Surgical Site Infection
Primary: Number of Subjects With Development of Surgical Site Infections — 9; 13 Participants
Phase 4 N=312 Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
End Stage Liver Disease · Hepatitis C
Primary: Freedom From Acute Rejection or HCV Recurrence or Treatment Failure — 69; 70; 133 participants
N/A N=11 Study Evaluating Liver Transplantation in Haemophilia Patients in Spain
Hemophilia · Hemophilia B
Primary: Number of Participants Requiring Immunosuppressive Therapy After Liver Transplantation — 7; 6; 4; 3 Participants
N/A N=160 Controlled Attenuation Parameter (CAP) in Liver Allografts
Liver Transplant · Liver Steatosis · Liver Disease
Primary: Controlled Attenuation Parameter (CAP) - Accuracy — 220 dB/m
Phase 2 N=62 Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients
End Stage Renal Disease
Primary: Number of Subjects Cured — 62 Participants
Phase 2 N=275 Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
Hepatitis C · Hepatitis C, Chronic · Nonimmune Nonviral Causes of Liver Failure
Primary: Number of Participants With Clinical Complications Usually Attributed to Immunosuppression — 12; 4 participants
Phase 4 N=10 Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors
End Stage Renal Disease · Hepatitis C
Primary: Viral Response as Assessed by Number of Participants With Undetectable Hepatitis C RNA — 10 Participants
Phase 4 N=30 Multi-center Study to Transplant Hepatitis-C Infected Kidneys
Renal Failure Chronic · Hepatitis C
Primary: Number of Participants With Undetectable HCV — 30 Participants
Phase 3 N=80 Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation
Reperfusion Injury · Liver Injury
Primary: Changed Rate of Liver Function Recovery Post-transplantation (Percent Change in AST Levels) — 83; 86.4 percentage change from baseline
Phase 2 N=15 Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction
Liver Transplant Recipient · Living Donor (of the Respective Liver Transplant Recipient)
Primary: Number of Participants Who Experienced Grade 3 or Higher Adverse Events (AEs) Deemed Attributable to darTreg Infusion — 0 Participants
Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Phase 3 N=284 Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
Liver Transplantation
Primary: Number of Participants With Composite Efficacy Failure of Treated Biopsy Proven Acute Rejection, Graft Loss or Death in Everolimus With Reduced Tacrolimus Group Compared…
N/A N=160 The Effect of Remote Ischemic Preconditioning in Living Donor Hepatectomy
Tissue Donors · Liver Transplantation · Ischemia Reperfusion Injury
Primary: Postopera The Maximal Aspartate Aminotransferase Level Within 7 Postoperative Days — 145; 152 IU/L
Phase 4 N=71 Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant
Asses Immunosuppression Modulation on Renal Recovery Post LT
Primary: Participants Who Have Recovered Renal Function — 28; 20; 11 Participants
Phase 2 N=40 Budesonide for Liver Transplant Immune Suppression
Acute Cellular Graft Rejection · New Onset Diabetes After Transplant
Primary: Number of Participants With Acute Cellular Rejection Between Study and Control Groups — 1; 1 Participants